MedTrace Logo

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

NCT04870606 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 733

Last updated 2024-01-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) as a treatment for outpatients COVID-19 subjects.

Conditions

  • Efficacy and Safety

Interventions

DRUG

Proxalutamide (GT0918)

Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory

DRUG

Placebo

Placebo+Standard of care determined by PI and local regulatory

Sponsors & Collaborators

  • Suzhou Kintor Pharmaceutical Inc,

    lead INDUSTRY

Principal Investigators

  • Wilson Lu · Suzhou Kintor Pharmaceuticals,Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2022-01-24
Completion
2022-04-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04870606 on ClinicalTrials.gov